Wednesday 23rd January 2013
|Text too small?|
Comvita, which uses produces health products from manuka honey and olive leaves, has bought an 85 hectare organic olive estate with potential to expand its production of olive leaf extracts by 130 percent over the next five years.
The price paid for Organic Olives (Aust) by Comvita's Australian subsidiary is undisclosed. The estate comprises some 7,000 certified organic olive trees, with room for further plantings, and is in Coominya, on the shores of Lake Wivenhoe in south-eastern Queensland
The company recently reported clinical trials at Auckland University's Liggins Institute had found a beneficial impact from its olive leaf extracts on secretion of insulin and the action of insulin in overweight men. The research has yet to be peer-reviewed and published, but is expected to boost global interest in the product.
"We're also scoping the possibility of building on this science, with additional clinical trials," said Comvita chief executive Brett Hewlett.
"The acquisition ... effectively future-proofs this rapidly growing part of our business. Together with fully developing our existing property, the development of our new purchase will provide the capacity to increase supply over the next five years by approximately 130 percent," said Hewlett.
Comvita shares last traded on the NZX at $3.65, although none changed hands immediately following the announcement.
DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to investor’s objectives, financial situation or needs. Before acting on any advice, investors should consider the appropriateness of the advice and IRG recommend that investors should obtain appropriate financial, legal and taxation advice before making any financial investment decision. The report is based on information compiled from public information and private research. IRG have completed the report on a best endeavours basis and do not accept any liability of loss or damage. IRG suggest that clients use this as part of a decision making process and check key data before making any investment decisions.
Employees may have an interest in the securities discussed in this report.
No comments yet
Comvita may not increase earnings in 2014 as higher honey prices bite, Craigs says
Comvita turned to a loss in first half, remains confident of increasing annual profit
Nasdaq-listed Derma Sciences takes 7.3 percent stake in Comvita in discounted placement
Comvita FY profit falls 10 percent , beating guidance, on honey shortage, rising costs
Comvita flags 15 percent fall in FY profit as expensive honey, supply shortages prompt downgrade
Comvita first-half earnings fall 7.4% amid short supply
Comvita buys Whanganui-based Kiwi Honey for undisclosed sum
Comvita hits 5-yr high on early results from diabetes trial
Comvita to seek deeper pool for directors' fees at AGM
Comvita's net profit surges to a record, dividend jumps